European Innovation Council

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for targeted cancer therapies. Founded in 2015, the company has established a proprietary drug delivery platform, Sagitta®, which enables the design of targeted drug candidates for various indications. RS Research's pipeline includes several proprietary programs in different stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. In addition to drug development, RS Research offers a range of services, including preclinical absorption, distribution, metabolism, and excretion studies, bioanalytical and analytical testing, and patent consulting. The company operates a GMP-certified production facility for clinical batch drug candidates and has successfully engaged in co-development projects with international partners, showcasing its commitment to advancing cancer treatment through modern therapeutic approaches.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Vigor Medical Technologies Ltd. focuses on developing and commercializing innovative devices aimed at treating chest trauma and facilitating thoracic and abdominal drainage. With over four million cases of chest trauma reported annually, which is a leading cause of accidental death, Vigor's products address a critical healthcare need. The company offers self-fixation sealing devices that prevent lung and heart collapse, essential for immediate and effective medical management. Additionally, Vigor has developed a hermetic seal and open drainage shaft that effectively seals wounds against contamination from dirt, blood, cloth, or hair, while also preventing both internal and external bleeding. These features make Vigor's devices valuable for military and civilian first aid organizations, as well as hospitals, enhancing the efficacy of emergency care in critical situations.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Cherry Biotech is a biomedical technology company specializing in Organ-on-Chip systems that facilitate drug discovery and personalized medicine. The company develops advanced microfluidic technologies to culture and replicate human organs under various physiological and pathological conditions. Additionally, Cherry Biotech provides temperature controllers to enable rapid temperature changes and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately mimicking the human cellular microenvironment, which is essential for drug development and toxicity assessments.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.

Kahun operates an online medical platform designed to assist healthcare organizations in improving the clinical intake process. By leveraging artificial intelligence, the platform catalogs clinical information from peer-reviewed medical literature and extracts relevant insights to facilitate informed decision-making by physicians. This approach optimizes the time doctors spend on documentation while enhancing their overall understanding of clinical knowledge. Ultimately, Kahun aims to improve clinical outcomes by providing a transparent and explainable system that supports efficient and effective diagnosis.

Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.

Piomic is a developer of a non-invasive medical device aimed at treating chronic wounds, particularly in patients with hard-to-heal leg and foot ulcers. The company's flagship product, the COMS® One Therapy System, is a portable, hand-held device that uses optical and magnetic stimulation technologies to promote wound healing. Clinical studies demonstrate that this device is safe and effective, leading to accelerated wound closure, reduced pain, and improved quality of life for patients. Designed for ease of use, the device features a single-button operation and can be utilized in various settings, including stationary and ambulatory facilities, as well as in patients’ homes. By focusing on a therapy that provides significant benefits, Piomic seeks to improve the treatment outcomes for individuals suffering from chronic wounds and alleviate the cost burden on healthcare systems.

Nuclidium focuses on enhancing cancer detection and staging to improve treatment options and long-term survival for patients. The company develops innovative radiopharmaceutical tracers aimed at targeting cancer diagnostics. Its platform allows for the identification of specific target molecules on tumors, enabling the application of therapeutic tracers with similar chemical properties and biological targets. This approach aims to facilitate affordable and effective personalized treatment for cancer patients, addressing significant unmet needs in the field.

Legacy Healthcare is focused on developing safer biotechnological solutions for the treatment of autoimmune and inflammatory diseases, particularly targeting moderate to severe alopecia areata, a condition that leads to significant hair loss and can result in lifelong challenges for patients. The company aims to create drugs that are effective yet safe for vulnerable populations, including children, cancer patients, and the elderly, who often deal with multiple medications for their conditions. By addressing these specific needs, Legacy Healthcare seeks to improve the quality of life for individuals affected by alopecia areata and advance innovative treatment options in the healthcare landscape.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

InVera Medical is a developer of innovative medical devices aimed at treating varicose veins and venous ulcers. The company focuses on creating less invasive, pain-free treatment options that leverage the body's natural biological responses. Their proprietary technology provides a minimally invasive endovenous treatment that enhances patient safety and efficacy, addressing a significant gap in the market where only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. With an estimated 3 million patients with venous ulcers currently underserved and reliant on ineffective compression bandaging, InVera Medical offers a solution that not only improves treatment outcomes but also seeks to reduce the substantial annual costs incurred by insurers. Their approach is positioned to disrupt conventional treatment practices and expand the indications for superficial venous ablation, ultimately enhancing access to effective care for a broader range of patients.

BrainEver focuses on developing innovative therapeutics for neurodegenerative disorders, rooted in the research of Alain Prochiantz and colleagues on brain development and physiology. The company explores the potential of homeoproteins, which are known to regulate neuronal functions throughout life, to enhance the physiological resistance and activity of surviving neurons in patients. This approach aims to improve clinical symptoms in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company is advancing its lead candidate, Engrailed 1 (BREN01), while also working on a pipeline of additional drug candidates targeting other neurodegenerative diseases, including Huntington's disease and optic neuropathies. By developing these novel therapeutics, BrainEver aims to provide effective treatment options for healthcare practitioners and patients affected by these challenging conditions.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.

YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.

Filterlex Medical Ltd., established in 2015 and based in Yokneam, Israel, specializes in developing embolic protection devices for reducing stroke and other complications during catheter-based structural heart procedures. Its flagship product, CAPTIS, is a full-body embolic protection device designed for intuitive deployment and retrieval. The company aims to address the limitations of existing products through its next-generation technology, which deflects, captures, and removes embolic particles, thereby minimizing procedural risks. Filterlex is currently seeking seed funding to support its innovative medical device startup in the cardiovascular field.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.

Op2Lysis is a company focused on developing a neurotic drug aimed at treating hemorrhagic strokes. Its primary product is a thrombolytic agent designed to dissolve the intracerebral hematoma that develops after such strokes. This innovative treatment can be administered locally through a catheter, utilizing micro-invasive surgical techniques. By effectively liquefying the hematoma, Op2Lysis's therapy aims to help patients avoid significant disabilities and the need for extensive surgical procedures.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Op2Lysis is a company focused on developing a neurotic drug aimed at treating hemorrhagic strokes. Its primary product is a thrombolytic agent designed to dissolve the intracerebral hematoma that develops after such strokes. This innovative treatment can be administered locally through a catheter, utilizing micro-invasive surgical techniques. By effectively liquefying the hematoma, Op2Lysis's therapy aims to help patients avoid significant disabilities and the need for extensive surgical procedures.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

PROSION is a biotechnology company focused on drug development, particularly in the area of cancer treatment and research. The company utilizes a proprietary platform that targets proline-rich motif binding domains, which are often associated with difficult-to-treat diseases. By employing innovative chemical building blocks, PROSION aims to unlock previously undruggable pharmaceutical targets linked to various pathologies, including cancer, diabetes, Alzheimer's, and cardiovascular diseases. This approach seeks to address significant unmet medical needs, ultimately enhancing treatment options and improving the survival and quality of life for patients.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Glycanostics is a start-up focused on developing early-stage cancer diagnostic tests, particularly for prostate cancer. The company is dedicated to creating clinically validated and registered affordable, non-invasive liquid biopsy tests. Their technology analyzes glycan changes on specific proteins, such as prostate-specific antigen (PSA), providing accurate insights that assist healthcare professionals in determining the necessity of a biopsy or monitoring patients post-biopsy. By emphasizing accessibility and precision in cancer diagnostics, Glycanostics aims to enhance early detection and improve patient outcomes in prostate cancer care.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

ADVITOS GmbH is a Munich-based company that specializes in the design, development, and marketing of extracorporeal multiple organ support therapies for hospitals in Germany. The company offers the ADVanced organ support treatment, a dialysis procedure that effectively removes a range of toxins from the liver, lungs, and kidneys, including water-soluble and protein-bound substances. The ADVOS method represents a pioneering approach to multi-organ support, combining the treatment of liver, lung, and kidney functions while also addressing acid-base balance. This method utilizes albumin dialysis to facilitate the fluid-based elimination of CO2, hepatic toxins, and nephrotoxins, correcting metabolic and respiratory acidosis without the need for gas exchangers. Founded in 2004, ADVITOS GmbH was previously known as Hepa Wash GmbH.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.